Skip to main content
OTCMKTS:ENZC

Enzolytics News Headlines

$0.12
+0.02 (+19.25 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.11
$0.13
50-Day Range
$0.10
$0.24
52-Week Range
$0.00
$0.96
Volume30.74 million shs
Average Volume42.15 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Enzolytics (OTCMKTS ENZC) News Headlines Today

SourceHeadline
Enzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US DollarsEnzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US Dollars
finance.yahoo.com - May 12 at 1:00 PM
Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Companys Strategic Communication FirmEnzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm
finance.yahoo.com - May 11 at 3:39 PM
Short Interest in Enzolytics Inc. (OTCMKTS:ENZC) Rises By 42.1%Short Interest in Enzolytics Inc. (OTCMKTS:ENZC) Rises By 42.1%
americanbankingnews.com - May 2 at 5:16 AM
Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and InitiativesEnzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
finance.yahoo.com - April 19 at 9:57 AM
Enzolytics to Present At the Emerging Growth Conference on April 14, 2021 - Yahoo FinanceEnzolytics to Present At the Emerging Growth Conference on April 14, 2021 - Yahoo Finance
finance.yahoo.com - April 12 at 12:08 PM
Enzolytics to Present At the Emerging Growth Conference on April 14, 2021Enzolytics to Present At the Emerging Growth Conference on April 14, 2021
finance.yahoo.com - April 12 at 12:08 PM
Coronavirus Targeted Epitopes Claimed in Enzolytics Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2) - Yahoo FinanceCoronavirus Targeted Epitopes Claimed in Enzolytics' Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2) - Yahoo Finance
finance.yahoo.com - April 5 at 1:31 PM
Coronavirus Targeted Epitopes Claimed in Enzolytics Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2)Coronavirus Targeted Epitopes Claimed in Enzolytics' Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2)
finance.yahoo.com - April 5 at 1:31 PM
Enzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates - Yahoo FinanceEnzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates - Yahoo Finance
finance.yahoo.com - March 22 at 12:25 PM
Enzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate UpdatesEnzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates
finance.yahoo.com - March 22 at 12:25 PM
Enzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting - Yahoo FinanceEnzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting - Yahoo Finance
finance.yahoo.com - March 16 at 6:41 PM
Enzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End ReportingEnzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting
finance.yahoo.com - March 16 at 1:40 PM
Enzolytics Is Surrounded By Controversy And Could Be Worthless - Seeking AlphaEnzolytics Is Surrounded By Controversy And Could Be Worthless - Seeking Alpha
seekingalpha.com - March 15 at 12:38 PM
Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus - Yahoo FinanceEnzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus - Yahoo Finance
finance.yahoo.com - March 8 at 12:39 PM
Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 VirusEnzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus
finance.yahoo.com - March 8 at 12:39 PM
Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus) - Yahoo FinanceEnzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus) - Yahoo Finance
finance.yahoo.com - February 22 at 2:21 PM
Enzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments - Yahoo FinanceEnzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments - Yahoo Finance
finance.yahoo.com - February 22 at 2:21 PM
Enzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other DevelopmentsEnzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments
finance.yahoo.com - February 22 at 2:21 PM
Enzolytics Announces the Discovery and Patenting of Eleven Newly  Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)
finance.yahoo.com - February 22 at 2:21 PM
Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases - Yahoo FinanceEnzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases - Yahoo Finance
finance.yahoo.com - February 17 at 1:57 PM
Enzolytics, Inc.: Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic DiseasesEnzolytics, Inc.: Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases
finanznachrichten.de - February 16 at 2:07 PM
Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic DiseasesEnzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases
finance.yahoo.com - February 16 at 2:07 PM
4 Penny Stocks on the Run: Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTC US: ALPP), Enzolytics (OTC US: ENZC), and Ocugen (NASDAQ: OCGN) - StreetInsider.com4 Penny Stocks on the Run: Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTC US: ALPP), Enzolytics (OTC US: ENZC), and Ocugen (NASDAQ: OCGN) - StreetInsider.com
streetinsider.com - February 10 at 12:28 PM
Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus - Yahoo FinanceEnzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus - Yahoo Finance
finance.yahoo.com - February 1 at 6:12 PM
Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV VirusEnzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus
finance.yahoo.com - February 1 at 1:11 PM
Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent ApplicationEnzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application
finance.yahoo.com - January 19 at 5:14 PM
Enzolytics IncEnzolytics Inc
bloomberg.com - January 17 at 9:25 PM
Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End AuditEnzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit
finance.yahoo.com - January 11 at 10:28 AM
Enzolytics, Inc. 2020 Year End UpdateEnzolytics, Inc. 2020 Year End Update
finance.yahoo.com - December 30 at 2:56 PM
News for Enzolytics Inc Registered ShsNews for Enzolytics Inc Registered Shs
markets.businessinsider.com - December 24 at 9:09 AM
Enzolytics Inc Registered Shs Stock , ENZCEnzolytics Inc Registered Shs Stock , ENZC
markets.businessinsider.com - December 23 at 11:46 PM
Enzolytics, Inc. Engages BTS Research to Conduct Toxicity StudyEnzolytics, Inc. Engages BTS Research to Conduct Toxicity Study
finance.yahoo.com - December 14 at 1:02 PM
Enzolytics, Inc. Files Provisional Patent for Treatment of Multiple SclerosisEnzolytics, Inc. Files Provisional Patent for Treatment of Multiple Sclerosis
finance.yahoo.com - December 10 at 4:29 PM
Enzolytics, Inc. Completes Merger with  BioClonetics Immunotherapeutics, Inc.Enzolytics, Inc. Completes Merger with BioClonetics Immunotherapeutics, Inc.
finance.yahoo.com - December 1 at 5:12 PM
Enzolytics Comments on Recent Market Activity and Shareholder UpdateEnzolytics Comments on Recent Market Activity and Shareholder Update
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics UpdateEnzolytics Update
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics, Inc. Announces Execution of Letter of Intent with BioClonetics Immunotherapeutics, Inc. (With Additional Update on 2020 Initiatives)Enzolytics, Inc. Announces Execution of Letter of Intent with BioClonetics Immunotherapeutics, Inc. (With Additional Update on 2020 Initiatives)
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics, Inc. Announces New Board Member, Charles Cotropia, CEO of BioClonetics Immunotherapeutics, Inc. Harry Zhabilov CEO of Enzolytics to Join Board of BioCloneticsEnzolytics, Inc. Announces New Board Member, Charles Cotropia, CEO of BioClonetics Immunotherapeutics, Inc. Harry Zhabilov CEO of Enzolytics to Join Board of BioClonetics
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc.Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc.
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics, Inc. Shares BioClonetics Immunotherapeutics, Inc. Company UpdateEnzolytics, Inc. Shares BioClonetics Immunotherapeutics, Inc. Company Update
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics, Inc. Announces Appointment of Charles Cotropia as CEO of ENZC and Harry Zhabilov as Its CSOEnzolytics, Inc. Announces Appointment of Charles Cotropia as CEO of ENZC and Harry Zhabilov as Its CSO
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics, Inc. Appoints Ronald Moss, M.D. to Its Medical Advisory BoardEnzolytics, Inc. Appoints Ronald Moss, M.D. to Its Medical Advisory Board
finance.yahoo.com - November 30 at 8:54 AM
Enzolytics Inc. Shares Current  BioClonetics Immunotherapeutics, Inc. UpdateEnzolytics Inc. Shares Current BioClonetics Immunotherapeutics, Inc. Update
finance.yahoo.com - November 30 at 8:54 AM
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.